Washington, D.C., October 31, 2004 – Investigators from Virco today presented data that establishes a comprehensive set of clinical cutoffs -- a newly established threshold for optimal selection and ...
COBAS TaqMan HIV-1 Test, v2.0 uses a dual-target approach to increase reliability. Roche’s COBAS® TaqMan® HIV-1 Test, v2.0, has been approved by the FDA. The test will be commercially available in the ...
NEW YORK (CBS.MW) -- Orasure Technologies climbed 6 percent in early trade after the Food and Drugs Administration approved its OraQuick Rapid HIV-1 Antibody Test for use in detecting HIV-1 antibodies ...
This retrospective study evaluated real-world implementation of the updated CDC HIV algorithm in a large US laboratory. Objectives: To understand real-world implementation of the updated CDC HIV ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo ® (lenacapavir)—the company’s twice ...
Fitness constraints on the HIV envelope protein are highly similar in humans and rhesus macaques, emphasizing the utility of macaque models of infection and antibody development.
– Positive Opinion Also Received for EMA’s EU-M4all Procedure, Designed to Facilitate Availability in Low- and Lower-Middle-Income Countries – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback